Product image of Invicorp (Phentolamine Mesilate, Aviptadil) supplied by GNH India

Invicorp

Active Ingredient:
Phentolamine Mesilate, Aviptadil
Origin:
EU

Invicorp (Phentolamine Mesilate, Aviptadil)

Phentolamine mesilate and aviptadil, the active ingredient in Invicorp, is a alpha‑adrenergic antagonist and vasoactive intestinal peptide analog presented as a solution for injection for intravenous use. It is employed in clinical settings to modulate vascular tone and inflammatory responses in hospitalized patients.

GNH India supplies Invicorp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Evolan Pharma Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Invicorp combines two agents that act on vascular and inflammatory pathways, making it suitable for several acute care scenarios.

  • Hypertensive emergencies: provides rapid vasodilation to lower dangerously high blood pressure.
  • Peri‑operative vascular support: helps maintain stable hemodynamics during surgery.
  • Pulmonary inflammatory conditions: offers bronchodilation and anti‑inflammatory effects in severe respiratory distress.

How It Works

  • Phentolamine mesilate blocks non‑selective alpha‑adrenergic receptors, preventing catecholamine‑induced vasoconstriction and producing systemic vasodilation. Aviptadil mimics endogenous vasoactive intestinal peptide, binding to VPAC receptors to trigger cyclic AMP pathways that cause vasodilation, bronchodilation, and modulation of inflammatory cytokine release. Together, they synergistically lower vascular resistance and attenuate inflammatory cascades.

Side Effects

Invicorp may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Hypotension: transient drop in blood pressure.
  • Flushing: warm sensation and reddening of skin.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Tachycardia: increased heart rate.
  • Injection site pain: local discomfort.

Serious or Rare Side Effects

  • Severe hypotension: risk of syncope or organ hypoperfusion.
  • Cardiac arrhythmias: irregular heart rhythms.
  • Myocardial ischemia: chest pain due to reduced coronary flow.
  • Anaphylaxis: acute allergic reaction with airway compromise.
  • Pulmonary edema: fluid accumulation in lungs.
  • Severe bronchospasm: worsening respiratory distress.

Precautions & Warnings

When using Invicorp, clinicians should observe several safety measures.

  • Blood pressure monitoring: check frequently to avoid excessive hypotension.
  • Cardiac disease caution: avoid in patients with unstable angina or recent myocardial infarction.
  • Drug interaction vigilance: be careful when co‑administered with other vasodilators or sympathomimetics.
  • Hypersensitivity assessment: discontinue if signs of allergic reaction appear.
  • Renal/hepatic function: adjust use in severe impairment as clearance may be altered.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Invicorp can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • MAO inhibitors: may cause unpredictable blood pressure changes.
  • Other potent vasodilators (e.g., nitroglycerin): risk of profound hypotension.
  • Beta‑blockers: can mask tachycardia while enhancing hypotensive effect.

Moderate Interactions (Monitor Closely)

  • Calcium channel blockers: additive blood pressure lowering.
  • ACE inhibitors or ARBs: may require dose adjustment.
  • Diuretics: can exacerbate volume depletion.
  • General anesthetics: may potentiate cardiovascular depression.

Frequently Asked Questions

Invicorp is a combination injectable containing phentolamine mesilate and aviptadil. It is used in acute care settings to provide rapid vasodilation, support vascular stability during surgery, and offer bronchodilatory and anti‑inflammatory effects in severe respiratory conditions.

Phentolamine mesilate blocks non‑selective alpha‑adrenergic receptors, preventing catecholamine‑induced vasoconstriction. This results in systemic vasodilation, lowering blood pressure and improving blood flow to vital organs.

The dose of Invicorp is determined by the prescribing clinician based on the patient’s condition, weight, and response. Healthcare professionals adjust the infusion rate and total volume according to clinical guidelines and individual needs.

Safety data for Invicorp in pregnancy or lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Invicorp, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Invicorp combines a non‑selective alpha‑blocker (phentolamine) with a VIP analog (aviptadil), offering both rapid blood pressure reduction and anti‑inflammatory bronchodilation. Unlike single‑agent vasodilators, it provides a broader therapeutic profile, which can be advantageous in complex critical‑care scenarios.

Invicorp should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability.

Invicorp is supplied as a sterile solution for injection and is administered intravenously. The infusion rate is set by the healthcare professional, typically using an infusion pump, and the patient is monitored continuously for hemodynamic changes.

The most serious risks include severe hypotension, cardiac arrhythmias, myocardial ischemia, anaphylactic reactions, and pulmonary edema. Prompt recognition and management of these events are essential, and patients should be monitored in a setting equipped for advanced cardiovascular support.

Invicorp is contraindicated in patients with known hypersensitivity to phentolamine, aviptadil, or any excipients in the formulation. It should also be avoided in individuals with uncontrolled severe cardiac disease, active severe hypotension, or those taking MAO inhibitors without appropriate medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Phentolamine Mesilate, Aviptadil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT